RWD88 Real-World Economic Burden Pre- and Post-Progression to Metastatic Castration-Resistant Prostate Cancer (mCRPC) and after First-Line mCRPC Therapy Initiation

Abstract

Patients with advanced prostate cancer (PC) may develop resistance to androgen deprivation therapy and progress to metastatic castration-resistant prostate cancer (mCRPC). Limited evidence exists characterizing real-world healthcare costs of patients with mCRPC. This study described healthcare costs of patients pre- and post-progression to mCRPC as well as after first-line (1L) mCRPC therapy initiation.